In conclusion, our study demonstrates that SYK inhibition in AML favors cell differentiation in MEK-ERK1/2 dependent manner, targets LSCs through modulation of OXPHOS metabolism and increases their sensitivity to cytarabine. The gene discussed is MAPK3; the disease is acute myeloid leukemia.